Key Takeaways
- BioNTech is expanding its oncology portfolio with antibodies and combination therapies, moving beyond its initial mRNA vaccine focus.
- Latest clinical data at the World Conference on Lung Cancer shows promising results for gotistobart in treating non-small cell lung cancer and supports pumitamig’s role as a potential oncology backbone.
- BioNTech’s collaboration with Bristol Myers Squibb on pumitamig positions it for a significant role in the global oncology market.
Shift in BioNTech’s Oncology Strategy
BioNTech is evolving from its initial focus on mRNA vaccines for COVID-19 to a broader oncology strategy involving antibodies, bispecifics, and combination therapies. Recent presentations at the World Conference on Lung Cancer in Seoul highlighted several key developments in its oncology pipeline.
One of the most significant advancements is gotistobart (BNT316/ONC-392), an anti-CTLA-4 antibody developed in partnership with OncoC4. In the Phase III PRESERVE-003 study, patients with previously treated squamous non-small cell lung cancer (NSCLC) achieved a median overall survival of 18.5 months with gotistobart, compared to 10 months with docetaxel. This finding represents a 54% reduction in the risk of death in a challenging patient population.
Gotistobart distinguishes itself from traditional CTLA-4 inhibitors by targeting CTLA-4-positive regulatory T cells specifically within the tumor microenvironment, potentially minimizing systemic toxicity. While promising, these results are preliminary and clinical validation is necessary for this candidate.
Another key development is pumitamig (BNT327/BMS-986545), a bispecific antibody targeting both PD-L1 and VEGF-A. After acquiring Biotheus, BioNTech is advancing pumitamig through a global partnership with Bristol Myers Squibb, which includes a significant upfront payment and additional milestone opportunities. Early Phase II data in unresectable mesothelioma suggest promising median progression-free survival (16.6 months) and overall survival (25.8 months), but caution is advised due to the study’s small sample size.
A particularly intriguing approach involves combining pumitamig with an antibody-drug conjugate (ADC), elfetabart drozuntecan (DB-1311/BNT324). Data presented indicated high response rates across treatment lines for NSCLC, with more than 80% of patients still in treatment at the time of the analysis. This multi-mechanistic strategy aims to enhance both immune activation and direct tumor-cell killing.
BioNTech’s strategy reflects a considerable transformation, aiming to develop a comprehensive oncology pipeline encompassing various therapeutic modalities. The company has launched over 16 clinical trials in lung cancer alone, including five Phase III studies.
Moving forward, the focus will be on clinical validation of gotistobart in its pivotal study and expanding pumitamig’s scope across larger, controlled trials. With BMS’s partnership, pumitamig stands as a cornerstone for BioNTech’s developing oncology franchise, aiming to transition from promising candidates to approved products in the competitive oncology landscape.
The content above is a summary. For more details, see the source article.